Clinical trial
Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or…
NCT00420381 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00420381 |
|---|---|
| Title | Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer |
| Official title | A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Carcinoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Gynecologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Neoplasms, Carcinoma |
| Intervention type | Drug |
| Interventions | enzastaurin |
| Enrollment | 28 |
| Start date | Jan 1, 2007 |
| Primary completion | May 1, 2008 |
| Completion | Dec 1, 2014 |
| First posted | Jan 11, 2007 |
| Last update posted | Dec 19, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: